CD8A and cancer: Studies have shown that, compared to Tex cells, CD8+TRM cells are often the primary responders to ICB therapy in various cancers, including hepatocellular carcinoma [220], head and neck squamous cell carcinoma [221], and triple‐negative breast cancer [222].